AustralieFrV1, PubMed, Checkpoint, bibRecord, 002F17

Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial.

Identifieur interne : 002F17 ( PubMed/Checkpoint ); précédent : 002F16; suivant : 002F18

Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial.

Auteurs : Stephen J. Nicholls [Australie] ; A Michael Lincoff [États-Unis] ; Philip J. Barter [Australie] ; H Bryan Brewer [États-Unis] ; Keith A A. Fox [Royaume-Uni] ; C Michael Gibson [États-Unis] ; Christopher Grainger [États-Unis] ; Venugopal Menon [États-Unis] ; Gilles Montalescot [France] ; Daniel Rader [États-Unis] ; Alan R. Tall [États-Unis] ; Ellen Mcerlean [États-Unis] ; Jeffrey Riesmeyer [États-Unis] ; Burkhard Vangerow [États-Unis] ; Giacomo Ruotolo [États-Unis] ; Govinda J. Weerakkody [États-Unis] ; Steven E. Nissen [États-Unis]

Source :

American heart journal [ 1097-6744 ] ; 2015.

RBID : pubmed:26678626

Descripteurs français

English descriptors

KwdEn :
- Anticholesteremic Agents (administration & dosage), Anticholesteremic Agents (adverse effects), Benzodiazepines (administration & dosage), Benzodiazepines (adverse effects), Cerebrovascular Disorders (diagnosis), Cerebrovascular Disorders (metabolism), Cerebrovascular Disorders (prevention & control), Cholesterol Ester Transfer Proteins (antagonists & inhibitors), Cholesterol Ester Transfer Proteins (metabolism), Cholesterol, HDL (blood), Cholesterol, LDL (blood), Coronary Artery Disease (diagnosis), Coronary Artery Disease (metabolism), Coronary Artery Disease (prevention & control), Double-Blind Method, Drug Monitoring, Female, Humans, Male, Middle Aged, Outcome Assessment (Health Care), Peripheral Vascular Diseases (diagnosis), Peripheral Vascular Diseases (metabolism), Peripheral Vascular Diseases (prevention & control), Risk Assessment.
MESH :
- chemical , administration & dosage : Anticholesteremic Agents, Benzodiazepines.
- chemical , adverse effects : Anticholesteremic Agents, Benzodiazepines.
- chemical , antagonists & inhibitors : Cholesterol Ester Transfer Proteins.
- chemical , blood : Cholesterol, HDL, Cholesterol, LDL.
- diagnosis : Cerebrovascular Disorders, Coronary Artery Disease, Peripheral Vascular Diseases.
- metabolism : Cerebrovascular Disorders, Cholesterol Ester Transfer Proteins, Coronary Artery Disease, Peripheral Vascular Diseases.
- prevention & control : Cerebrovascular Disorders, Coronary Artery Disease, Peripheral Vascular Diseases.
- Double-Blind Method, Drug Monitoring, Female, Humans, Male, Middle Aged, Outcome Assessment (Health Care), Risk Assessment.

Abstract

Potent pharmacologic inhibition of cholesteryl ester transferase protein by the investigational agent evacetrapib increases high-density lipoprotein cholesterol by 54% to 129%, reduces low-density lipoprotein cholesterol by 14% to 36%, and enhances cellular cholesterol efflux capacity. The ACCELERATE trial examines whether the addition of evacetrapib to standard medical therapy reduces the risk of cardiovascular (CV) morbidity and mortality in patients with high-risk vascular disease.

DOI: 10.1016/j.ahj.2015.09.007
PubMed: 26678626

Affiliations:

Australie, France, Royaume-Uni, États-Unis
Caroline du Nord, Indiana, Maryland, Massachusetts, Nouvelle-Galles du Sud, Ohio, Pennsylvanie, Écosse, État de New York, Île-de-France
Paris, Sydney

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 002584
to stream PubMed, to step Curation: 002515

Links to Exploration step

pubmed:26678626

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial.</title>
<author><name sortKey="Nicholls, Stephen J" sort="Nicholls, Stephen J" uniqKey="Nicholls S" first="Stephen J" last="Nicholls">Stephen J. Nicholls</name>
<affiliation wicri:level="1"><nlm:affiliation>South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>South Australian Health and Medical Research Institute, University of Adelaide, Adelaide</wicri:regionArea>
<wicri:noRegion>Adelaide</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lincoff, A Michael" sort="Lincoff, A Michael" uniqKey="Lincoff A" first="A Michael" last="Lincoff">A Michael Lincoff</name>
<affiliation wicri:level="2"><nlm:affiliation>Cleveland Clinic Coordinating Center for Clinical Research and Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
<wicri:cityArea>Cleveland Clinic Coordinating Center for Clinical Research and Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Barter, Philip J" sort="Barter, Philip J" uniqKey="Barter P" first="Philip J" last="Barter">Philip J. Barter</name>
<affiliation wicri:level="3"><nlm:affiliation>University of New South Wales, Sydney, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>University of New South Wales, Sydney</wicri:regionArea>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brewer, H Bryan" sort="Brewer, H Bryan" uniqKey="Brewer H" first="H Bryan" last="Brewer">H Bryan Brewer</name>
<affiliation wicri:level="2"><nlm:affiliation>Medstar Research Institute, Hyattsville, MD.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>Medstar Research Institute, Hyattsville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Fox, Keith A A" sort="Fox, Keith A A" uniqKey="Fox K" first="Keith A A" last="Fox">Keith A A. Fox</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Edinburgh, Edinburgh, Scotland.</nlm:affiliation>
<country>Royaume-Uni</country>
<placeName><region type="country">Écosse</region>
</placeName>
<wicri:cityArea>University of Edinburgh, Edinburgh</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Gibson, C Michael" sort="Gibson, C Michael" uniqKey="Gibson C" first="C Michael" last="Gibson">C Michael Gibson</name>
<affiliation wicri:level="2"><nlm:affiliation>Harvard Medical School, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Grainger, Christopher" sort="Grainger, Christopher" uniqKey="Grainger C" first="Christopher" last="Grainger">Christopher Grainger</name>
<affiliation wicri:level="2"><nlm:affiliation>Duke Clinical Research Institute, Durham, NC.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
<wicri:cityArea>Duke Clinical Research Institute, Durham</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Menon, Venugopal" sort="Menon, Venugopal" uniqKey="Menon V" first="Venugopal" last="Menon">Venugopal Menon</name>
<affiliation wicri:level="2"><nlm:affiliation>Cleveland Clinic Coordinating Center for Clinical Research and Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
<wicri:cityArea>Cleveland Clinic Coordinating Center for Clinical Research and Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Montalescot, Gilles" sort="Montalescot, Gilles" uniqKey="Montalescot G" first="Gilles" last="Montalescot">Gilles Montalescot</name>
<affiliation wicri:level="3"><nlm:affiliation>Pitie-Salpetriere University Hospital, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Pitie-Salpetriere University Hospital, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rader, Daniel" sort="Rader, Daniel" uniqKey="Rader D" first="Daniel" last="Rader">Daniel Rader</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Pennsylvania, Philadelphia, PA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>University of Pennsylvania, Philadelphia</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Tall, Alan R" sort="Tall, Alan R" uniqKey="Tall A" first="Alan R" last="Tall">Alan R. Tall</name>
<affiliation wicri:level="2"><nlm:affiliation>Columbia University, New York City, NY.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Columbia University, New York City</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Mcerlean, Ellen" sort="Mcerlean, Ellen" uniqKey="Mcerlean E" first="Ellen" last="Mcerlean">Ellen Mcerlean</name>
<affiliation wicri:level="2"><nlm:affiliation>Cleveland Clinic Coordinating Center for Clinical Research and Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
<wicri:cityArea>Cleveland Clinic Coordinating Center for Clinical Research and Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Riesmeyer, Jeffrey" sort="Riesmeyer, Jeffrey" uniqKey="Riesmeyer J" first="Jeffrey" last="Riesmeyer">Jeffrey Riesmeyer</name>
<affiliation wicri:level="2"><nlm:affiliation>Eli Lilly and Company, Indianapolis, IN.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Indiana</region>
</placeName>
<wicri:cityArea>Eli Lilly and Company, Indianapolis</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Vangerow, Burkhard" sort="Vangerow, Burkhard" uniqKey="Vangerow B" first="Burkhard" last="Vangerow">Burkhard Vangerow</name>
<affiliation wicri:level="2"><nlm:affiliation>Eli Lilly and Company, Indianapolis, IN.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Indiana</region>
</placeName>
<wicri:cityArea>Eli Lilly and Company, Indianapolis</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Ruotolo, Giacomo" sort="Ruotolo, Giacomo" uniqKey="Ruotolo G" first="Giacomo" last="Ruotolo">Giacomo Ruotolo</name>
<affiliation wicri:level="2"><nlm:affiliation>Eli Lilly and Company, Indianapolis, IN.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Indiana</region>
</placeName>
<wicri:cityArea>Eli Lilly and Company, Indianapolis</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Weerakkody, Govinda J" sort="Weerakkody, Govinda J" uniqKey="Weerakkody G" first="Govinda J" last="Weerakkody">Govinda J. Weerakkody</name>
<affiliation wicri:level="2"><nlm:affiliation>Eli Lilly and Company, Indianapolis, IN.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Indiana</region>
</placeName>
<wicri:cityArea>Eli Lilly and Company, Indianapolis</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Nissen, Steven E" sort="Nissen, Steven E" uniqKey="Nissen S" first="Steven E" last="Nissen">Steven E. Nissen</name>
<affiliation wicri:level="2"><nlm:affiliation>Cleveland Clinic Coordinating Center for Clinical Research and Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
<wicri:cityArea>Cleveland Clinic Coordinating Center for Clinical Research and Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland</wicri:cityArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:26678626</idno>
<idno type="pmid">26678626</idno>
<idno type="doi">10.1016/j.ahj.2015.09.007</idno>
<idno type="wicri:Area/PubMed/Corpus">002584</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002584</idno>
<idno type="wicri:Area/PubMed/Curation">002515</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002515</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002515</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002515</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial.</title>
<author><name sortKey="Nicholls, Stephen J" sort="Nicholls, Stephen J" uniqKey="Nicholls S" first="Stephen J" last="Nicholls">Stephen J. Nicholls</name>
<affiliation wicri:level="1"><nlm:affiliation>South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>South Australian Health and Medical Research Institute, University of Adelaide, Adelaide</wicri:regionArea>
<wicri:noRegion>Adelaide</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lincoff, A Michael" sort="Lincoff, A Michael" uniqKey="Lincoff A" first="A Michael" last="Lincoff">A Michael Lincoff</name>
<affiliation wicri:level="2"><nlm:affiliation>Cleveland Clinic Coordinating Center for Clinical Research and Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
<wicri:cityArea>Cleveland Clinic Coordinating Center for Clinical Research and Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Barter, Philip J" sort="Barter, Philip J" uniqKey="Barter P" first="Philip J" last="Barter">Philip J. Barter</name>
<affiliation wicri:level="3"><nlm:affiliation>University of New South Wales, Sydney, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>University of New South Wales, Sydney</wicri:regionArea>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brewer, H Bryan" sort="Brewer, H Bryan" uniqKey="Brewer H" first="H Bryan" last="Brewer">H Bryan Brewer</name>
<affiliation wicri:level="2"><nlm:affiliation>Medstar Research Institute, Hyattsville, MD.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>Medstar Research Institute, Hyattsville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Fox, Keith A A" sort="Fox, Keith A A" uniqKey="Fox K" first="Keith A A" last="Fox">Keith A A. Fox</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Edinburgh, Edinburgh, Scotland.</nlm:affiliation>
<country>Royaume-Uni</country>
<placeName><region type="country">Écosse</region>
</placeName>
<wicri:cityArea>University of Edinburgh, Edinburgh</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Gibson, C Michael" sort="Gibson, C Michael" uniqKey="Gibson C" first="C Michael" last="Gibson">C Michael Gibson</name>
<affiliation wicri:level="2"><nlm:affiliation>Harvard Medical School, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Grainger, Christopher" sort="Grainger, Christopher" uniqKey="Grainger C" first="Christopher" last="Grainger">Christopher Grainger</name>
<affiliation wicri:level="2"><nlm:affiliation>Duke Clinical Research Institute, Durham, NC.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
<wicri:cityArea>Duke Clinical Research Institute, Durham</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Menon, Venugopal" sort="Menon, Venugopal" uniqKey="Menon V" first="Venugopal" last="Menon">Venugopal Menon</name>
<affiliation wicri:level="2"><nlm:affiliation>Cleveland Clinic Coordinating Center for Clinical Research and Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
<wicri:cityArea>Cleveland Clinic Coordinating Center for Clinical Research and Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Montalescot, Gilles" sort="Montalescot, Gilles" uniqKey="Montalescot G" first="Gilles" last="Montalescot">Gilles Montalescot</name>
<affiliation wicri:level="3"><nlm:affiliation>Pitie-Salpetriere University Hospital, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Pitie-Salpetriere University Hospital, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rader, Daniel" sort="Rader, Daniel" uniqKey="Rader D" first="Daniel" last="Rader">Daniel Rader</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Pennsylvania, Philadelphia, PA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>University of Pennsylvania, Philadelphia</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Tall, Alan R" sort="Tall, Alan R" uniqKey="Tall A" first="Alan R" last="Tall">Alan R. Tall</name>
<affiliation wicri:level="2"><nlm:affiliation>Columbia University, New York City, NY.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Columbia University, New York City</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Mcerlean, Ellen" sort="Mcerlean, Ellen" uniqKey="Mcerlean E" first="Ellen" last="Mcerlean">Ellen Mcerlean</name>
<affiliation wicri:level="2"><nlm:affiliation>Cleveland Clinic Coordinating Center for Clinical Research and Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
<wicri:cityArea>Cleveland Clinic Coordinating Center for Clinical Research and Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Riesmeyer, Jeffrey" sort="Riesmeyer, Jeffrey" uniqKey="Riesmeyer J" first="Jeffrey" last="Riesmeyer">Jeffrey Riesmeyer</name>
<affiliation wicri:level="2"><nlm:affiliation>Eli Lilly and Company, Indianapolis, IN.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Indiana</region>
</placeName>
<wicri:cityArea>Eli Lilly and Company, Indianapolis</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Vangerow, Burkhard" sort="Vangerow, Burkhard" uniqKey="Vangerow B" first="Burkhard" last="Vangerow">Burkhard Vangerow</name>
<affiliation wicri:level="2"><nlm:affiliation>Eli Lilly and Company, Indianapolis, IN.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Indiana</region>
</placeName>
<wicri:cityArea>Eli Lilly and Company, Indianapolis</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Ruotolo, Giacomo" sort="Ruotolo, Giacomo" uniqKey="Ruotolo G" first="Giacomo" last="Ruotolo">Giacomo Ruotolo</name>
<affiliation wicri:level="2"><nlm:affiliation>Eli Lilly and Company, Indianapolis, IN.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Indiana</region>
</placeName>
<wicri:cityArea>Eli Lilly and Company, Indianapolis</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Weerakkody, Govinda J" sort="Weerakkody, Govinda J" uniqKey="Weerakkody G" first="Govinda J" last="Weerakkody">Govinda J. Weerakkody</name>
<affiliation wicri:level="2"><nlm:affiliation>Eli Lilly and Company, Indianapolis, IN.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Indiana</region>
</placeName>
<wicri:cityArea>Eli Lilly and Company, Indianapolis</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Nissen, Steven E" sort="Nissen, Steven E" uniqKey="Nissen S" first="Steven E" last="Nissen">Steven E. Nissen</name>
<affiliation wicri:level="2"><nlm:affiliation>Cleveland Clinic Coordinating Center for Clinical Research and Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
<wicri:cityArea>Cleveland Clinic Coordinating Center for Clinical Research and Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland</wicri:cityArea>
</affiliation>
</author>
</analytic>
<series><title level="j">American heart journal</title>
<idno type="eISSN">1097-6744</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anticholesteremic Agents (administration & dosage)</term>
<term>Anticholesteremic Agents (adverse effects)</term>
<term>Benzodiazepines (administration & dosage)</term>
<term>Benzodiazepines (adverse effects)</term>
<term>Cerebrovascular Disorders (diagnosis)</term>
<term>Cerebrovascular Disorders (metabolism)</term>
<term>Cerebrovascular Disorders (prevention & control)</term>
<term>Cholesterol Ester Transfer Proteins (antagonists & inhibitors)</term>
<term>Cholesterol Ester Transfer Proteins (metabolism)</term>
<term>Cholesterol, HDL (blood)</term>
<term>Cholesterol, LDL (blood)</term>
<term>Coronary Artery Disease (diagnosis)</term>
<term>Coronary Artery Disease (metabolism)</term>
<term>Coronary Artery Disease (prevention & control)</term>
<term>Double-Blind Method</term>
<term>Drug Monitoring</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Outcome Assessment (Health Care)</term>
<term>Peripheral Vascular Diseases (diagnosis)</term>
<term>Peripheral Vascular Diseases (metabolism)</term>
<term>Peripheral Vascular Diseases (prevention & control)</term>
<term>Risk Assessment</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Angiopathies intracrâniennes ()</term>
<term>Angiopathies intracrâniennes (diagnostic)</term>
<term>Angiopathies intracrâniennes (métabolisme)</term>
<term>Anticholestérolémiants (administration et posologie)</term>
<term>Anticholestérolémiants (effets indésirables)</term>
<term>Benzodiazépines (administration et posologie)</term>
<term>Benzodiazépines (effets indésirables)</term>
<term>Cholestérol HDL (sang)</term>
<term>Cholestérol LDL (sang)</term>
<term>Femelle</term>
<term>Humains</term>
<term>Maladie des artères coronaires ()</term>
<term>Maladie des artères coronaires (diagnostic)</term>
<term>Maladie des artères coronaires (métabolisme)</term>
<term>Maladies vasculaires périphériques ()</term>
<term>Maladies vasculaires périphériques (diagnostic)</term>
<term>Maladies vasculaires périphériques (métabolisme)</term>
<term>Mâle</term>
<term>Méthode en double aveugle</term>
<term>Protéines de transfert des esters de cholestérol (antagonistes et inhibiteurs)</term>
<term>Protéines de transfert des esters de cholestérol (métabolisme)</term>
<term>Surveillance pharmacologique</term>
<term>Évaluation de résultat (soins)</term>
<term>Évaluation des risques</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anticholesteremic Agents</term>
<term>Benzodiazepines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anticholesteremic Agents</term>
<term>Benzodiazepines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Cholesterol Ester Transfer Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Cholesterol, HDL</term>
<term>Cholesterol, LDL</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anticholestérolémiants</term>
<term>Benzodiazépines</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Protéines de transfert des esters de cholestérol</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Cerebrovascular Disorders</term>
<term>Coronary Artery Disease</term>
<term>Peripheral Vascular Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Angiopathies intracrâniennes</term>
<term>Maladie des artères coronaires</term>
<term>Maladies vasculaires périphériques</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Anticholestérolémiants</term>
<term>Benzodiazépines</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Cerebrovascular Disorders</term>
<term>Cholesterol Ester Transfer Proteins</term>
<term>Coronary Artery Disease</term>
<term>Peripheral Vascular Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Angiopathies intracrâniennes</term>
<term>Maladie des artères coronaires</term>
<term>Maladies vasculaires périphériques</term>
<term>Protéines de transfert des esters de cholestérol</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Cerebrovascular Disorders</term>
<term>Coronary Artery Disease</term>
<term>Peripheral Vascular Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Cholestérol HDL</term>
<term>Cholestérol LDL</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Double-Blind Method</term>
<term>Drug Monitoring</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Outcome Assessment (Health Care)</term>
<term>Risk Assessment</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Angiopathies intracrâniennes</term>
<term>Femelle</term>
<term>Humains</term>
<term>Maladie des artères coronaires</term>
<term>Maladies vasculaires périphériques</term>
<term>Mâle</term>
<term>Méthode en double aveugle</term>
<term>Surveillance pharmacologique</term>
<term>Évaluation de résultat (soins)</term>
<term>Évaluation des risques</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Potent pharmacologic inhibition of cholesteryl ester transferase protein by the investigational agent evacetrapib increases high-density lipoprotein cholesterol by 54% to 129%, reduces low-density lipoprotein cholesterol by 14% to 36%, and enhances cellular cholesterol efflux capacity. The ACCELERATE trial examines whether the addition of evacetrapib to standard medical therapy reduces the risk of cardiovascular (CV) morbidity and mortality in patients with high-risk vascular disease.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26678626</PMID>
<DateCreated><Year>2015</Year>
<Month>12</Month>
<Day>18</Day>
</DateCreated>
<DateCompleted><Year>2016</Year>
<Month>04</Month>
<Day>21</Day>
</DateCompleted>
<DateRevised><Year>2015</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-6744</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>170</Volume>
<Issue>6</Issue>
<PubDate><Year>2015</Year>
<Month>Dec</Month>
</PubDate>
</JournalIssue>
<Title>American heart journal</Title>
<ISOAbbreviation>Am. Heart J.</ISOAbbreviation>
</Journal>
<ArticleTitle>Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial.</ArticleTitle>
<Pagination><MedlinePgn>1061-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ahj.2015.09.007</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0002-8703(15)00593-1</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Potent pharmacologic inhibition of cholesteryl ester transferase protein by the investigational agent evacetrapib increases high-density lipoprotein cholesterol by 54% to 129%, reduces low-density lipoprotein cholesterol by 14% to 36%, and enhances cellular cholesterol efflux capacity. The ACCELERATE trial examines whether the addition of evacetrapib to standard medical therapy reduces the risk of cardiovascular (CV) morbidity and mortality in patients with high-risk vascular disease.</AbstractText>
<AbstractText Label="STUDY DESIGN" NlmCategory="METHODS">ACCELERATE is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Patients qualified for enrollment if they have experienced an acute coronary syndrome within the prior 30 to 365 days, cerebrovascular accident, or transient ischemic attack; if they have peripheral vascular disease; or they have diabetes with coronary artery disease. A total of 12,092 patients were randomized to evacetrapib 130 mg or placebo daily in addition to standard medical therapy. The primary efficacy end point is time to first event of CV death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization. Treatment will continue until 1,670 patients reached the primary end point; at least 700 patients reach the key secondary efficacy end point of CV death, myocardial infarction, and stroke, and the last patient randomized has been followed up for at least 1.5 years.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">ACCELERATE will establish whether the cholesteryl ester transfer protein inhibition by evacetrapib improves CV outcomes in patients with high-risk vascular disease.</AbstractText>
<CopyrightInformation>Copyright © 2015 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nicholls</LastName>
<ForeName>Stephen J</ForeName>
<Initials>SJ</Initials>
<AffiliationInfo><Affiliation>South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lincoff</LastName>
<ForeName>A Michael</ForeName>
<Initials>AM</Initials>
<AffiliationInfo><Affiliation>Cleveland Clinic Coordinating Center for Clinical Research and Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Barter</LastName>
<ForeName>Philip J</ForeName>
<Initials>PJ</Initials>
<AffiliationInfo><Affiliation>University of New South Wales, Sydney, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Brewer</LastName>
<ForeName>H Bryan</ForeName>
<Initials>HB</Initials>
<AffiliationInfo><Affiliation>Medstar Research Institute, Hyattsville, MD.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Fox</LastName>
<ForeName>Keith A A</ForeName>
<Initials>KA</Initials>
<AffiliationInfo><Affiliation>University of Edinburgh, Edinburgh, Scotland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gibson</LastName>
<ForeName>C Michael</ForeName>
<Initials>CM</Initials>
<AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Grainger</LastName>
<ForeName>Christopher</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Duke Clinical Research Institute, Durham, NC.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Menon</LastName>
<ForeName>Venugopal</ForeName>
<Initials>V</Initials>
<AffiliationInfo><Affiliation>Cleveland Clinic Coordinating Center for Clinical Research and Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Montalescot</LastName>
<ForeName>Gilles</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Pitie-Salpetriere University Hospital, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rader</LastName>
<ForeName>Daniel</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>University of Pennsylvania, Philadelphia, PA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tall</LastName>
<ForeName>Alan R</ForeName>
<Initials>AR</Initials>
<AffiliationInfo><Affiliation>Columbia University, New York City, NY.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>McErlean</LastName>
<ForeName>Ellen</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Cleveland Clinic Coordinating Center for Clinical Research and Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Riesmeyer</LastName>
<ForeName>Jeffrey</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Vangerow</LastName>
<ForeName>Burkhard</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ruotolo</LastName>
<ForeName>Giacomo</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Weerakkody</LastName>
<ForeName>Govinda J</ForeName>
<Initials>GJ</Initials>
<AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Nissen</LastName>
<ForeName>Steven E</ForeName>
<Initials>SE</Initials>
<AffiliationInfo><Affiliation>Cleveland Clinic Coordinating Center for Clinical Research and Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2015</Year>
<Month>09</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Am Heart J</MedlineTA>
<NlmUniqueID>0370465</NlmUniqueID>
<ISSNLinking>0002-8703</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000924">Anticholesteremic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053480">Cholesterol Ester Transfer Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008076">Cholesterol, HDL</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008078">Cholesterol, LDL</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>12794-10-4</RegistryNumber>
<NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>51XWV9K850</RegistryNumber>
<NameOfSubstance UI="C568301">evacetrapib</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000924" MajorTopicYN="N">Anticholesteremic Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001569" MajorTopicYN="Y">Benzodiazepines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002561" MajorTopicYN="N">Cerebrovascular Disorders</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053480" MajorTopicYN="Y">Cholesterol Ester Transfer Proteins</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008076" MajorTopicYN="N">Cholesterol, HDL</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008078" MajorTopicYN="N">Cholesterol, LDL</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003324" MajorTopicYN="N">Coronary Artery Disease</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016903" MajorTopicYN="N">Drug Monitoring</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment (Health Care)</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016491" MajorTopicYN="N">Peripheral Vascular Diseases</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year>
<Month>07</Month>
<Day>09</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2015</Year>
<Month>09</Month>
<Day>14</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2015</Year>
<Month>12</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2015</Year>
<Month>12</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>4</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">26678626</ArticleId>
<ArticleId IdType="pii">S0002-8703(15)00593-1</ArticleId>
<ArticleId IdType="doi">10.1016/j.ahj.2015.09.007</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Australie</li>
<li>France</li>
<li>Royaume-Uni</li>
<li>États-Unis</li>
</country>
<region><li>Caroline du Nord</li>
<li>Indiana</li>
<li>Maryland</li>
<li>Massachusetts</li>
<li>Nouvelle-Galles du Sud</li>
<li>Ohio</li>
<li>Pennsylvanie</li>
<li>Écosse</li>
<li>État de New York</li>
<li>Île-de-France</li>
</region>
<settlement><li>Paris</li>
<li>Sydney</li>
</settlement>
</list>
<tree><country name="Australie"><noRegion><name sortKey="Nicholls, Stephen J" sort="Nicholls, Stephen J" uniqKey="Nicholls S" first="Stephen J" last="Nicholls">Stephen J. Nicholls</name>
</noRegion>
<name sortKey="Barter, Philip J" sort="Barter, Philip J" uniqKey="Barter P" first="Philip J" last="Barter">Philip J. Barter</name>
</country>
<country name="États-Unis"><region name="Ohio"><name sortKey="Lincoff, A Michael" sort="Lincoff, A Michael" uniqKey="Lincoff A" first="A Michael" last="Lincoff">A Michael Lincoff</name>
</region>
<name sortKey="Brewer, H Bryan" sort="Brewer, H Bryan" uniqKey="Brewer H" first="H Bryan" last="Brewer">H Bryan Brewer</name>
<name sortKey="Gibson, C Michael" sort="Gibson, C Michael" uniqKey="Gibson C" first="C Michael" last="Gibson">C Michael Gibson</name>
<name sortKey="Grainger, Christopher" sort="Grainger, Christopher" uniqKey="Grainger C" first="Christopher" last="Grainger">Christopher Grainger</name>
<name sortKey="Mcerlean, Ellen" sort="Mcerlean, Ellen" uniqKey="Mcerlean E" first="Ellen" last="Mcerlean">Ellen Mcerlean</name>
<name sortKey="Menon, Venugopal" sort="Menon, Venugopal" uniqKey="Menon V" first="Venugopal" last="Menon">Venugopal Menon</name>
<name sortKey="Nissen, Steven E" sort="Nissen, Steven E" uniqKey="Nissen S" first="Steven E" last="Nissen">Steven E. Nissen</name>
<name sortKey="Rader, Daniel" sort="Rader, Daniel" uniqKey="Rader D" first="Daniel" last="Rader">Daniel Rader</name>
<name sortKey="Riesmeyer, Jeffrey" sort="Riesmeyer, Jeffrey" uniqKey="Riesmeyer J" first="Jeffrey" last="Riesmeyer">Jeffrey Riesmeyer</name>
<name sortKey="Ruotolo, Giacomo" sort="Ruotolo, Giacomo" uniqKey="Ruotolo G" first="Giacomo" last="Ruotolo">Giacomo Ruotolo</name>
<name sortKey="Tall, Alan R" sort="Tall, Alan R" uniqKey="Tall A" first="Alan R" last="Tall">Alan R. Tall</name>
<name sortKey="Vangerow, Burkhard" sort="Vangerow, Burkhard" uniqKey="Vangerow B" first="Burkhard" last="Vangerow">Burkhard Vangerow</name>
<name sortKey="Weerakkody, Govinda J" sort="Weerakkody, Govinda J" uniqKey="Weerakkody G" first="Govinda J" last="Weerakkody">Govinda J. Weerakkody</name>
</country>
<country name="Royaume-Uni"><region name="Écosse"><name sortKey="Fox, Keith A A" sort="Fox, Keith A A" uniqKey="Fox K" first="Keith A A" last="Fox">Keith A A. Fox</name>
</region>
</country>
<country name="France"><region name="Île-de-France"><name sortKey="Montalescot, Gilles" sort="Montalescot, Gilles" uniqKey="Montalescot G" first="Gilles" last="Montalescot">Gilles Montalescot</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F17 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002F17 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:26678626
   |texte=   Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:26678626" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial.

Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki